Previewing the 2nd Half of 2020…and Other Updates From The Week

Greetings from...wait for it...Ashland Oregon. Yes, it was so good, we came back for more. The weather here is great, the riding is outstanding...

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595...

Tailwinds' Take: with the trial being open-label, INmune has been able to see the data all along. Therefore, one can assume that they are...

Happy 4th of July…A Review of June and Other Notes

With June closing out, we can now reflect on what was the best quarter the stock market has seen since the turn of the...

Summer is Coming

When you receive this newsletter, it will be June 21st, the official start of summer. Typically for stocks you have a summer doldrums, "sell...

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial...

Tailwinds' Take: first-in-man for their second product line is a major accomplishment for the Company. By targeting the innate immune system's NK cells, INKmune...

June Preview…Plus Much More!

May was another strong month for the market as the stimulus package and expectations for a strong re-opening of the economy kept the rebound...

This Week’s Recap: Skinny Trails, Anixa Looks Primed, Atomera Launching

As most readers know by now, I love mountain biking. It's great exercise and there's a tremendous thrill to hitting a difficult stretch of...

Killers at the Crossroad – A Published Review of Innate Immune Cell Potential in...

Tailwinds' Take: the scientific publication linked here is a great summation of the potential of NK cells in fighting cancer. INMB's INKmune program has...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

Tailwinds' Take: submitting an IND for Covid-19 this month is the biggest potential near term driver, but there are lots of shots on goal...

INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response...

Tailwinds' Take: further evidence of the broad-scale applications possible by reducing soluble TNF and associated inflammation. INB03 has the potential to be used in...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

The Eye Of The Storm…This Week In Tailwinds’ World

Well, I've been expecting it and it appears that it's here. The market put up one of its best months ever in April, but...

Anixa and INmune: Unique COVID-19 Opportunities In Tailwinds’ Universe

CoronaVirus is not only the buzzword for the whole market both on the negative side as business falls off a cliff, and positively as...

This Week in Stocks

While the markets may not have had the most volatile week of the year, nor come close, it was a very topsy-turvy five days...

Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer

Tailwinds' Take: more evidence on the negative role that soluble TNF plays in many diseases. INMB's ability to neutralize soluble TNF without associated immuno-supression...

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In...

Tailwinds' Take: patents show the uniqueness of INKmune, which is set to start two clinical trials this year. INMB is one of the most...

INmune Bio (INMD) Conference Call on COVID19 Program Transcript

INmune Bio DN-TNF Clinical Trial, Complications of Cytokine Storm Caused by COVID-19 April 20, 2020 Presenter R.J. Tesi, CEO and Chief Medical Officer David Moss, CFO Q&A Participants John Aschoff -...

INmune Addresses COVID-19

Monday morning, INmune Bio (INMB) announced that they were pursuing a clinical program to determine if the Company’s TNF Inhibitor (DN-TNF) platform could help...

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if...

Tailwinds' Take: this Phase II trial is going to happen quickly. Inflammation is a big part of the problems associated with CV19 and INmune's...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.